Menin is an important co-factor of oncogenic MLL fusion proteins, and the menin-MLL interactions are essential to study the development of acute leukemia in vivo. Targeting the menin-MLL interactions with small molecules provides an attractive strategy for the development of new anticancer agents. The accurate determination of menin crystal structures and the development of potential small molecule and peptide mimetic inhibitors demonstrate the feasibility of targeting menin-MLL interactions. Furthermore, MLL binds to menin in a complex bivalent mode involving two MLL motifs. Efforts on targeting the menin-MLL interactions have revealed that potential benefit of blocking menin in cancer.
BOC Sciences is focused on investigating menin-MLL interactions and exploring menin-MLL inhibitors to develop a Menin/MLL targeted library.
Figure 1. Menin is involved in a diverse network of protein-protein interactions. (Cierpicki, T.; Grembecka, Jolanta. 2014)
At BOC Sciences, our well-trained scientific staffs have generated a high-throughput virtual screening method based on docking approach to generate this library:
Figure 2. Structures of small molecule inhibitors bound to menin. (Cierpicki, T.; Grembecka, J. 2014)
BOC Sciences provides professional, rapid and high-quality services of Menin/MLL Targeted Library design at competitive prices for global customers. Personalized and customized services of Menin/MLL Targeted Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
BOC Sciences has rich experience in working with global customers in custom library synthesis of compounds and generating small to medium-sized libraries of target compounds. Our knowledge in generating a large number of target molecules in a remarkably shorter time enables quick biological screenings for affinities. With the target properties in mind, we deliver target molecules, by applying our extensive knowledge in drug discovery.